Literature DB >> 18951793

3D QSAR CoMFA/CoMSIA, molecular docking and molecular dynamics studies of fullerene-based HIV-1 PR inhibitors.

Serdar Durdagi1, Thomas Mavromoustakos, Manthos G Papadopoulos.   

Abstract

For the first time, a set of experimentally reported [60] fullerene derivatives were subjected to the 3D-QSAR/CoMFA and CoMSIA studies. The aim of this study is to propose a series of novel [60] fullerene-based inhibitors with optimal binding affinity for the HIV-1 PR enzyme. The position of the template molecule at the cavity of HIV-1 PR was optimized and 3D QSAR models were developed. Relative contributions of steric/electrostatic fields of the 3D-QSAR/CoMFA and CoMSIA models have shown that steric effects govern the bioactivity of the compounds, but electrostatic interactions play also an important role.The de novo drug design Leapfrog simulations provided a series of novel compounds with predicted improved inhibition effect.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18951793     DOI: 10.1016/j.bmcl.2008.09.107

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  12 in total

1.  Binding of novel fullerene inhibitors to HIV-1 protease: insight through molecular dynamics and molecular mechanics Poisson-Boltzmann surface area calculations.

Authors:  Haralambos Tzoupis; Georgios Leonis; Serdar Durdagi; Varnavas Mouchlis; Thomas Mavromoustakos; Manthos G Papadopoulos
Journal:  J Comput Aided Mol Des       Date:  2011-10-04       Impact factor: 3.686

2.  CORAL: QSPR models for solubility of [C60] and [C70] fullerene derivatives.

Authors:  Alla P Toropova; Andrey A Toropov; Emilio Benfenati; Giuseppina Gini; Danuta Leszczynska; Jerzy Leszczynski
Journal:  Mol Divers       Date:  2010-03-27       Impact factor: 2.943

3.  3D-QSAR studies and molecular docking on [5-(4-amino-1H-benzoimidazol-2-yl)-furan-2-yl]-phosphonic acid derivatives as fructose-1,6-biphophatase inhibitors.

Authors:  Ping Lan; Mei-Qi Xie; Yue-Mei Yao; Wan-Na Chen; Wei-Min Chen
Journal:  J Comput Aided Mol Des       Date:  2010-10-20       Impact factor: 3.686

4.  Computational studies of the binding mechanisms of fullerenes to human serum albumin.

Authors:  Jinyu Li; Lizhi Jiang; Xiaolei Zhu
Journal:  J Mol Model       Date:  2015-06-21       Impact factor: 1.810

5.  Molecular modeling studies of 4,5-dihydro-1H-pyrazolo[4,3-h] quinazoline derivatives as potent CDK2/Cyclin a inhibitors using 3D-QSAR and docking.

Authors:  Yong Ai; Shao-Teng Wang; Ping-Hua Sun; Fa-Jun Song
Journal:  Int J Mol Sci       Date:  2010-09-28       Impact factor: 5.923

Review 6.  Molecular modeling in structural nano-toxicology: interactions of nano-particles with nano-machinery of cells.

Authors:  Naveena Yanamala; Valerian E Kagan; Anna A Shvedova
Journal:  Adv Drug Deliv Rev       Date:  2013-05-28       Impact factor: 15.470

7.  Novel design strategy for checkpoint kinase 2 inhibitors using pharmacophore modeling, combinatorial fusion, and virtual screening.

Authors:  Chun-Yuan Lin; Yen-Ling Wang
Journal:  Biomed Res Int       Date:  2014-04-23       Impact factor: 3.411

8.  Advantages and limitations of classic and 3D QSAR approaches in nano-QSAR studies based on biological activity of fullerene derivatives.

Authors:  Karolina Jagiello; Monika Grzonkowska; Marta Swirog; Lucky Ahmed; Bakhtiyor Rasulev; Aggelos Avramopoulos; Manthos G Papadopoulos; Jerzy Leszczynski; Tomasz Puzyn
Journal:  J Nanopart Res       Date:  2016-08-29       Impact factor: 2.253

9.  Structural insight into the binding of C60-derivatives with enoyl-pyruvate transferase from Helicobacter pylori.

Authors:  Mohammad Teimouri; Muhammad Junaid; Abbas Khan; Houjin Zhang
Journal:  Bioinformation       Date:  2017-06-30

10.  Prediction and evaluation of the lipase inhibitory activities of tea polyphenols with 3D-QSAR models.

Authors:  Yi-Fang Li; Yi-Qun Chang; Jie Deng; Wei-Xi Li; Jie Jian; Jia-Suo Gao; Xin Wan; Hao Gao; Hiroshi Kurihara; Ping-Hua Sun; Rong-Rong He
Journal:  Sci Rep       Date:  2016-10-03       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.